Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer


Submitted: January 25, 2016
Accepted: February 11, 2016
Published: March 31, 2016
Abstract Views: 2367
PDF: 1120
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Not available.

Supporting Agencies

The TROPIC study was sponsored by Sanofi. Editorial support in the preparation of this letter was provided by Danielle Lindley of MediTech Media funded by Sanofi.

de Bono, J., Shen, L., & Sartor, O. (2016). Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Archivio Italiano Di Urologia E Andrologia, 88(1), 72–73. https://doi.org/10.4081/aiua.2016.1.72

Downloads

Download data is not yet available.

Citations